Fan Chang-Fa, Mei Xing-Guo
Beijing Institute of Pharmacology and Toxicology, 27 Taiping Road, 100850 Beijing, PR China.
Vaccine. 2005 Aug 15;23(35):4453-61. doi: 10.1016/j.vaccine.2005.03.044.
With the goal to develop effective immunogens against infection of respiratory syncytial virus (RSV), vectors co-expressing chimeric CTL epitope or G protein fragment of RSV with carrier protein DsbA (disulfide bond isomerase) were constructed. The capacity of the expressed recombinant immunogens to induce cellular and humoral immunities were evaluated. It was demonstrated that the presence of G protein fragment was able to enhance the CTL activities induced by the chimeric CTL epitope, though G protein fragment alone had no effect on induction of CTL response. In contrast, the level of antibody response to RSV and neutralization titer in co-immunization with G protein fragment plus chimeric CTL epitope was lower than that in immunization with G protein fragment alone. The challenge experiments indicated that co-immunization further reduced RSV titers both in lung tissue and nasal track, indicating the combination of humoral and cellular immunities is more effective. This data imply that the combination of the two protein immunogens would be a viable strategy for a RSV vaccine.
为了开发针对呼吸道合胞病毒（RSV）感染的有效免疫原，构建了与载体蛋白DsbA（二硫键异构酶）共表达RSV嵌合CTL表位或G蛋白片段的载体。对表达的重组免疫原诱导细胞免疫和体液免疫的能力进行了评估。结果表明，G蛋白片段的存在能够增强嵌合CTL表位诱导的CTL活性，尽管单独的G蛋白片段对CTL反应的诱导没有影响。相反，G蛋白片段与嵌合CTL表位共同免疫时，对RSV的抗体反应水平和中和效价低于单独用G蛋白片段免疫时。攻毒实验表明，共同免疫进一步降低了肺组织和鼻道中的RSV滴度，表明体液免疫和细胞免疫的联合更有效。这些数据表明，两种蛋白免疫原的联合将是一种可行的RSV疫苗策略。
